Asian Hedge Fund Manager, Long Short Equity, Macro

David Mudd

Asian Hedge Fund manager based in HK/SG with over 20 years of experience managing Asian Long/Short Equity funds. Macroeconomic top-down analysis generates thematic investments that are further researched from the bottom-up. Research is supplemented with advanced technical analysis. 
Previous experience includes M&A with Morgan Stanley and CPA with Deloitte in NYC. Wharton MBA.

CanSino Biologics(6185 HK): Price Surged - Worth a Shot !!

The Heat Is On: News Flow and Sentiment in CHINA / HONG KONG (August 2026)

Technically Speaking Breakouts & Breakdowns - HONG KONG (August 2026)

The Heat Is On: News Flow and Sentiment in CHINA / HONG KONG (June 2026)

CHINA/US: Trump Wages Another Losing War, This Time in Tech!

Equity Bottom-Up

<ul>
<li>China's CXO sector is growing rapidly, with China's dominant companies providing critical services to global pharmaceutical companies.  New modalities, particularly GLP-1/TIDES, ADCs, and bispecific antibodies, are structural demand drivers.</li>
<li>The biggest overhang for the sector, the US BioSecure Act, is overblown due to the US pharma industry's substantial structural dependency on China's CXO sector.</li>
<li>Pharmaron's investment case rests on three interlocking pillars: an irreplaceable integrated platform, a landmark commercial anchor in the GLP-1 supercycle, and the structural impossibility of a rapid US-China CXO decoupling.</li>
</ul>


China's CXO sector is growing rapidly, with China's dominant companies providing critical services to global pharmaceutical companies.  New modalities, particularly GLP-1/TIDES, ADCs, and bispecific antibodies, are structural demand drivers.
The biggest overhang for the sector, the US BioSecure Act, is overblown due to the US pharma industry's substantial structural dependency on China's CXO sector.
Pharmaron's investment case rests on three interlocking pillars: an irreplaceable integrated platform, a landmark commercial anchor in the GLP-1 supercycle, and the structural impossibility of a rapid US-China CXO decoupling.


Hangzhou Tigermed Consulting (A) (300347 CH)

CHINA BIOTECH SECTOR: Pharmaron's One Stop Shop!